Volume 15, Number 10—October 2009
Letter
Severe Necrotizing Pneumonia in Children, Houston, Texas, USA
Anupama S. Kalaskar
, Gloria P. Heresi, Audrey Wanger, James R. Murphy, and Susan H. Wootton
, Gloria P. Heresi, Audrey Wanger, James R. Murphy, and Susan H. Wootton
Table
Characteristics of patients in study of severe necrotizing pneumonia in children, Houston, Texas, USA, 2007–2008*
| Characteristic | Patient |
|||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Age, y | 4.1 | 2.8 | 3.4 | 3.7 |
| Race | Black | White | Black | Black |
| Sex | M | M | F | F |
| Completed PCV-7 series | Yes | Yes | Yes | Yes |
| Co-illnesses |
Asthma |
None |
None |
None |
| Clinical signs | ||||
| Date | 2007 Nov | 2007 Nov | 2007 Dec | 2008 Feb |
| Temperature, °C | 37.6 | 38.9 | 37.9 | 38.7 |
| Pulse, beats/min | 154 | 160 | 162 | 188 |
| Respiratory rate, breaths/min | 70 | 60 | 40 | 42 |
| Blood pressure, mm Hg | 95/53 | 122/84 | 110/78 | 106/69 |
| Oxygen saturation on room air, % |
85 |
90 |
100 |
86 |
| Symptoms/signs (hospital) |
Fever, cough, dyspnea, headache, abdominal pain, decreased activity |
Fever, cough, dyspnea, congestion |
Fever, cough |
Fever, cough, decreased appetite |
| Hospital course | ||||
| Site pathogen isolated | Blood and pleural fluid | Blood and pleural fluid | Pleural fluid | Blood |
| IV antimicrobial drugs, d | 21 | 9 | 14 | 33 |
| IV antimicrobial drugs (MIC, μg/mL) | Cefotaxime (0.06) | Vancomycin (0.75); ceftriaxone (0.19) | Vancomycin (1); resistant to cephalosporin | Vancomycin (0.50); ceftriaxone (0.064) |
| VATS† (duration, d) | Yes (2) | Yes (2) | Yes (2) | No |
| ICU stay | Yes | Yes | No | Yes |
| Intubated (duration, d) | Yes (5) | Yes (5) | No | Yes (22) |
| Duration of hospitalization, d |
22 |
11 |
15 |
28 |
| Oral antimicrobial drugs after discharge (duration, d) | Cefdinir (7) | Cefdinir (14) | Linezolid (14) | Cefdinir (7) |
*PCV, pneumococcal conjugate vaccine; IV, intravenous; VATS, video-assisted thoracoscopic surgery; ICU, intensive care unit. Boldface indicates clinically significant differences.
†Hospitalization day that VATS was performed.
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.